ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
ARS Pharmaceuticals (NASDAQ: SPRY), a biopharmaceutical company focused on developing solutions for anaphylaxis prevention, has announced its participation in three upcoming investor conferences in June 2025:
- William Blair 45th Annual Growth Stock Conference in Chicago on June 3, 2025 at 11:20 a.m. CT
- 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025 at 5:30 p.m. ET
- Scotiabank Third Annual Healthcare Canadian Investor Day in Toronto on June 17, 2025
Company executives Richard Lowenthal (Co-Founder, President and CEO) and Eric Karas (Chief Commercial Officer) will lead presentations at the William Blair and Jefferies conferences. Live and archived webcasts will be available on the company's website for 30 days following each event.
ARS Pharmaceuticals (NASDAQ: SPRY), un'azienda biofarmaceutica specializzata nello sviluppo di soluzioni per la prevenzione dell'anafilassi, ha annunciato la sua partecipazione a tre conferenze per investitori previste per giugno 2025:
- William Blair 45th Annual Growth Stock Conference a Chicago il 3 giugno 2025 alle 11:20 a.m. CT
- 2025 Jefferies Global Healthcare Conference a New York City il 4 giugno 2025 alle 5:30 p.m. ET
- Scotiabank Third Annual Healthcare Canadian Investor Day a Toronto il 17 giugno 2025
I dirigenti dell'azienda Richard Lowenthal (Co-Fondatore, Presidente e CEO) ed Eric Karas (Chief Commercial Officer) guideranno le presentazioni alle conferenze William Blair e Jefferies. Le webcasting in diretta e registrate saranno disponibili sul sito web dell'azienda per 30 giorni dopo ogni evento.
ARS Pharmaceuticals (NASDAQ: SPRY), una compañía biofarmacéutica enfocada en desarrollar soluciones para la prevención de la anafilaxia, ha anunciado su participación en tres próximas conferencias para inversores en junio de 2025:
- William Blair 45th Annual Growth Stock Conference en Chicago el 3 de junio de 2025 a las 11:20 a.m. CT
- 2025 Jefferies Global Healthcare Conference en Nueva York el 4 de junio de 2025 a las 5:30 p.m. ET
- Scotiabank Third Annual Healthcare Canadian Investor Day en Toronto el 17 de junio de 2025
Los ejecutivos de la empresa Richard Lowenthal (Co-Fundador, Presidente y CEO) y Eric Karas (Director Comercial) liderarán las presentaciones en las conferencias William Blair y Jefferies. Las transmisiones web en vivo y archivadas estarán disponibles en el sitio web de la compañía durante 30 días después de cada evento.
ARS Pharmaceuticals (NASDAQ: SPRY)는 아나필락시스 예방 솔루션 개발에 주력하는 바이오제약 회사로, 2025년 6월에 열리는 세 개의 투자자 컨퍼런스에 참여한다고 발표했습니다:
- William Blair 제45회 연례 성장주 컨퍼런스 - 2025년 6월 3일 오전 11:20 CT, 시카고
- 2025 Jefferies 글로벌 헬스케어 컨퍼런스 - 2025년 6월 4일 오후 5:30 ET, 뉴욕시
- Scotiabank 제3회 연례 헬스케어 캐나다 투자자 데이 - 2025년 6월 17일, 토론토
회사 경영진인 Richard Lowenthal(공동 창립자, 사장 겸 CEO)과 Eric Karas(최고 상업 책임자)가 William Blair 및 Jefferies 컨퍼런스에서 발표를 이끌 예정입니다. 각 행사 후 30일간 회사 웹사이트에서 생중계 및 녹화된 웹캐스트를 시청할 수 있습니다.
ARS Pharmaceuticals (NASDAQ : SPRY), une société biopharmaceutique spécialisée dans le développement de solutions pour la prévention de l'anaphylaxie, a annoncé sa participation à trois prochaines conférences pour investisseurs en juin 2025 :
- William Blair 45th Annual Growth Stock Conference à Chicago le 3 juin 2025 à 11h20 CT
- 2025 Jefferies Global Healthcare Conference à New York City le 4 juin 2025 à 17h30 ET
- Scotiabank Third Annual Healthcare Canadian Investor Day à Toronto le 17 juin 2025
Les dirigeants de l'entreprise, Richard Lowenthal (cofondateur, président et PDG) et Eric Karas (directeur commercial), animeront les présentations lors des conférences William Blair et Jefferies. Les webdiffusions en direct et archivées seront disponibles sur le site web de la société pendant 30 jours après chaque événement.
ARS Pharmaceuticals (NASDAQ: SPRY), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Lösungen zur Verhinderung von Anaphylaxie spezialisiert hat, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im Juni 2025 bekanntgegeben:
- William Blair 45th Annual Growth Stock Conference in Chicago am 3. Juni 2025 um 11:20 Uhr CT
- 2025 Jefferies Global Healthcare Conference in New York City am 4. Juni 2025 um 17:30 Uhr ET
- Scotiabank Third Annual Healthcare Canadian Investor Day in Toronto am 17. Juni 2025
Die Unternehmensleiter Richard Lowenthal (Mitbegründer, Präsident und CEO) und Eric Karas (Chief Commercial Officer) werden die Präsentationen auf den William Blair- und Jefferies-Konferenzen leiten. Live- und aufgezeichnete Webcasts werden auf der Unternehmenswebsite für 30 Tage nach jeder Veranstaltung verfügbar sein.
- None.
- None.
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June.
Details outlined below.
William Blair 45th Annual Growth Stock Conference
Presentation: Tuesday, June 3, 2025
Time: 11:20 a.m. CT
Location: Chicago
A live webcast of the presentation will be available here.
2025 Jefferies Global Healthcare Conference
Presentation: Wednesday, June 4, 2025
Time: 5:30 p.m. ET
Location: New York City
A live webcast of the presentation will be available here.
ARS Pharma company management will also participate in one-on-one meetings with investors at the Scotiabank Third Annual Healthcare Canadian Investor Day, Tuesday, June 17, 2025, in Toronto.
To access the live and archived webcasts for the investor conferences, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay of each of the webcasts will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668
